BRIEF published on 08/10/2026 at 08:35, 3 months ago Innate Pharma Advances Lacutamab into Phase 3 Trial with Sobi Innate Pharma Lacutamab Phase 3 TELLOMAK-3 Markus Jensen Sobi Partnership
PRESS RELEASE published on 08/10/2026 at 08:30, 3 months ago Informations privilégiées / Autres communiqués Innate Pharma fait progresser Lacutamab vers la phase 3 suite au partenariat avec Sobi et nomme un nouveau directeur médical. Démarrage de l'étude TELLOMAK-3 pour le syndrome de Sézary Partenariat Phase 3 Innate Pharma Directeur Médical Lacutamab
BRIEF published on 05/19/2026 at 07:05, 5 months 22 days ago Innate Pharma to Attend Jefferies Global Healthcare Conference Biotechnology Cancer Treatment Immunotherapy Innate Pharma Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 5 months 22 days ago Innate Pharma at the Jefferies Global Healthcare Conference Immunotherapy Cancer Innate Pharma Therapeutic Antibodies Jefferies Conference
BRIEF published on 05/19/2026 at 07:05, 5 months 22 days ago Innate Pharma participera à la conférence mondiale sur les soins de santé de Jefferies Biotechnologie Immunothérapie Traitement Du Cancer Innate Pharma Conférence Jefferies
BRIEF published on 05/19/2026 at 07:05, 5 months 22 days ago Innate Pharma à la Conférence Jefferies Global Healthcare Immunothérapie Cancer Innate Pharma Conférence Jefferies Anticorps Thérapeutiques
PRESS RELEASE published on 05/19/2026 at 07:00, 5 months 22 days ago Inside Information / Other news releases Innate Pharma to participate in Jefferies Global Healthcare Conference on June 2-4, 2026 in New York, United States. Developing immunotherapies for cancer patients Biotechnology Innate Pharma Jefferies Global Healthcare Conference Immunothérapies Cancer Patients
PRESS RELEASE published on 05/19/2026 at 07:00, 5 months 22 days ago Informations privilégiées / Autres communiqués Innate Pharma participera à la conférence Jefferies Global Healthcare 2026 à New York. La société de biotechnologies développe des traitements d'immunothérapies contre le cancer Conference Cancer Innate Pharma Biotechnologies Immunothérapies
BRIEF published on 04/17/2026 at 21:05, 6 months 23 days ago Innate Pharma dévoile des résultats intermédiaires prometteurs dans l'étude de phase 2 MATISSE Essais Cliniques Cancer Du Poumon Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 6 months 23 days ago Innate Pharma présente des résultats intermédiaires de l'essai MATISSE au congrès AACR Cancer Du Poumon Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
Published on 11/10/2026 at 21:00, 19 minutes ago Golden Minerals Announces Completion of Offering for C$5,000,000
Published on 11/10/2026 at 14:45, 6 hours 34 minutes ago An Investigational Drug to Tackle Measles Outbreaks
Published on 11/10/2026 at 14:31, 6 hours 48 minutes ago First Breach Plans to Integrate Onboard AI Computing into CQS and LRS Drone Platforms
Published on 11/10/2026 at 14:30, 6 hours 49 minutes ago Stabilis Solutions Announces Three-Year Take-Or-Pay LNG Supply Agreement with Existing Aerospace Customer
Published on 11/10/2026 at 14:30, 6 hours 49 minutes ago ACCESS Newswire Reports Third Quarter 2026 Results
Published on 11/10/2026 at 19:21, 1 hour 57 minutes ago ALTHEORA, Mäder Composites France et IPC s'associent pour donner une seconde vie aux matériaux composites
Published on 11/10/2026 at 18:54, 2 hours 24 minutes ago REPLOID Group AG pursues entry in the US market and secures exclusivity to conduct due diligence for the potential acquisition of Chapul, LLC.
Published on 11/10/2026 at 18:45, 2 hours 34 minutes ago Special Optics Introduces Purpose-Built Microscope Objectives for Quantum Applications
Published on 11/10/2026 at 18:30, 2 hours 49 minutes ago Shelly Group Accelerates Revenue Growth in the Third Quarter and Confirms Full-Year 2026 Guidance
Published on 11/10/2026 at 18:00, 3 hours 19 minutes ago Déclaration du nombre total des droits de vote et du nombre d’actions au 31 octobre 2026
Published on 11/10/2026 at 17:45, 3 hours 34 minutes ago Damartex / Descriptif du programme de rachat d'actions
Published on 11/10/2026 at 17:35, 3 hours 44 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 31 octobre 2026
Published on 11/10/2026 at 17:31, 3 hours 47 minutes ago CNP Assurances SA annonce le succès de l’émission d’une obligation subordonnée Tier 2 de 500 M€.
